AstraZeneca agreed to pay $110 million to settle two lawsuits in the US claiming that the company fraudulently marketed Seroquel (quetiapine) and Crestor (rosuvastatin). “While we deny the allegations, it is in the best interests of the company to resolve these matters…while avoiding the delay, uncertainty and expense of protracted litigation,” the drugmaker said.
Under the settlements with the state of Texas, AstraZeneca will pay $90 million to resolve allegations that the company encouraged doctors to use Seroquel for unapproved uses and $20 million to cover claims related to Crestor. Texas had sought $5 billion under the lawsuits, claiming that AstraZeneca had falsely and misleadingly marketed the two drugs.
